Sanofi - 22 Year Stock Split History | SNY

Stock split history for Sanofi since 2002. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Sanofi Annual Stock Splits
Sanofi Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $128.207B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $814.944B 117.78
Novo Nordisk (NVO) Denmark $590.290B 45.36
Johnson & Johnson (JNJ) United States $372.289B 14.76
Merck (MRK) United States $318.551B 57.96
AbbVie (ABBV) United States $304.294B 15.72
AstraZeneca (AZN) United Kingdom $244.043B 21.22
Novartis AG (NVS) Switzerland $216.930B 15.08
Pfizer (PFE) United States $169.828B 21.11
Innoviva (INVA) United States $1.073B 7.54